Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding,
pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18
years of age with serious bacterial infections
Phase:
Phase 1
Details
Lead Sponsor:
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)